Rizankizumab

Red

Brand Name(s):Skyrizi

Indication:Psoriasis (moderate to severe) in adults who are candidates for systemic therapy

Rationale:

Considered:Sep-19

Review Date:Sep-24

Comments:
NICE has recommended risankizumab as an option for treating severe plaque psoriasis in adults (PASI >10; DLQI >10) if disease has not responded to systemic treatments (ciclosporin, methotrexate and phototherapy), or these are contraindicated/not tolerated; https://www.nice.org.uk/guidance/ta596